SILVER SPRING, Md., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) today announced that its Chief Executive Officer (CEO), Kenneth L Waggoner, JD, and its Chief Operating Officer, Gerald W. Crabtree, Ph.D., will be attending the 2015 Gastrointestinal Cancers Symposium, "Bridging Cancer Biology to Clinical GI Oncology," to be held in the Moscone West Convention Center in San Francisco, California, January 15-17, 2015.
Nuvilex's CEO, Kenneth L. Waggoner, stated, "Our attendance at this pivotal Symposium, which is dedicated to recent advances in the treatment of cancers of the GI tract, is essential because a substantial portion of the Symposium will be dedicated to the treatment of pancreatic cancer and because a significant component of Nuvilex's portfolio is devoted to the development of treatments for this deadly disease and the symptoms associated with it. The treatments Nuvilex will employ to attack pancreatic cancer are based on the use of the proprietary Cell-in-a-Box® cellulose-based live cell encapsulation technology in combination with low doses of the anticancer prodrug ifosfamide that has been deemed effective in two previous clinical trials. Our targeted chemotherapy platform has now shown encouraging results in early preclinical studies in the U.S. performed by Translational Drug Development (TD2) that are concerned with the development of malignant ascites fluid in animals with an abdominal cancer."
The Gastrointestinal Cancers Symposium is an annual event held in January in San Francisco and is co-sponsored by the American Gastroenterological Association, the American Society of Clinical Oncology, the American Society of Radiation Oncology, the American Society for Radiation Oncology and the Society of Surgical Oncology. This Symposium is expected to attract over 3,000 participants from around the world who are experts in the treatment of cancers of the pancreas, small bowel, colon, rectum, hepatobiliary tract, esophagus and stomach. At this event, many of the latest developments in the prevention, screening, diagnosis, multidisciplinary treatment and translational research of GI cancers will be presented.
Nuvilex is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, Nuvilex is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. Nuvilex is also developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. In doing so, Nuvilex is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Nuvilex the rare opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, could cause actual results to differ materially from those set forth in the forward-looking statements. They include Nuvilex's ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex's intellectual property and Nuvilex's continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting Investor Relations.
CONTACT: Investor Relations Contacts: Jamien Jones Blueprint Life Science Group Telephone: 415.375.3340 Ext. 103 firstname.lastname@example.org